Company / Working Capital
Spyre Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$719.1M
FY2025
5-year range
$47.6M / $719.1M
FY2021-FY2025
Trend
+29.7%
vs FY2024
Sector context
#61 of 213
Health Care
What the data says
At $719M, Spyre Therapeutics, Inc.'s working capital ranks #61 of 213 in the Health Care sector. Working Capital has increased for 3 consecutive years, from $48M in FY2022 to $719M in FY2025.
Based on SEC 10-K filings.
$719M in FY2025 with a 5-year CAGR of +40.1%.
Improved from $310M to $719M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +147.2%
- 5-Year CAGR
- +40.1%
- 10-Year CAGR
- -
Sector benchmark
#61 of 213 in Health CareTop 29% of 213This company $719.1M Sector average $934.6M
▼
-23.1% below sector average
Key checks
Key Insights
- Spyre Therapeutics, Inc.'s working capital has grown for 3 consecutive years.
- 5-year CAGR of +40.1%, indicating consistent growth.
- In FY2025, working capital increased 29.7% year-over-year.
- Ranks #61 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $719.1M | +29.7% |
| FY2024 | $554.4M | +79.1% |
| FY2023 | $309.6M | +550.3% |
| FY2022 | $47.6M | -39.6% |
| FY2021 | $78.7M | -40.9% |
| FY2020 | $133.3M | +137.5% |
| FY2019 | $56.1M | -15.5% |
| FY2018 | $66.4M | +34.6% |
| FY2017 | $49.4M | -21.0% |
| FY2016 | $62.5M | +74.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026